ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1420	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	hereditary prostate cancer 0.542395 prostate biopsy 0.533126 dutasteride group vs 0.459041 skin cancer 0.446356 prostate cancer period 0.528407 cancer mortality rates 0.459369 prostate volume subgroups 0.508967 Prostate Cancer Events 0.558338 finasteride group versus 0.448086 rat ventral prostate 0.516053 high-grade tumors 0.479135 high-grade cancer 0.454168 prostate cancer-specific mortality 0.525559 occult prostate cancer 0.561891 high-grade prostate cancer 0.548137 prostate preventive effects 0.507979 relative risk reduction 0.446967 radical prostatectomy 0.460894 prostate cancer mortality 0.534065 prostate cancer chemoprevention 0.531007 dietary fat 0.445789 men 0.4492 Cancer Events trial 0.451937 negative prostate biopsy 0.515564	digital rectal examination 0.454846 dutasteride group 0.460003 fat intake 0.450377 Cancer Prevention Trial 0.500983 prostate digital 0.500034 prostate cancer risk 0.564597 placebo group 0.469544 incident prostate cancer 0.532469 Cancer Events study 0.447937 prostate volume 0.517049 absolute risk reduction 0.495169 low biologic risk 0.447169 finasteride group 0.448145 prostate cancer 0.910772 Gleason 0.458954 clinical prostate cancer 0.556069 pancake-appearing prostate 0.508749 Prostate Cancer Prevention 0.595277 prostate cancer. 0.505972 prostate cancer death. 0.562581 statistically significant difference 0.470146 prostate cancers 0.559985 human prostate cancer 0.538634	CLICK HERE
1618	National Cancer Institute	Html	en	Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version	The treatment of cancer may cause health problems (late effects) for childhood cancer survivors months or years after successful treatment has ended. Get information about the long-term physical, psychological and social effects of treatment for childhood cancer in this expert-reviewed summary.	childhood cancers 0.431043 cancer treatment 0.371211 body 0.373967 childhood cancer survivors 0.770496 chemotherapy 0.372336 PDQ cancer information 0.35879 total-body irradiation 0.354372 ovarian late effects 0.364333 bile duct 0.348106 talk 0.386582 chest radiation treatment 0.353115 kidney late effects 0.373747 joint late effects 0.365129 cancer information summary 0.349224 stem cell transplant 0.480939 pancreatic late effects 0.367016 heart 0.364096 symptoms 0.373794 health problems 0.529948 tests 0.430651 primary cancer diagnosis 0.352818 radiation therapy 0.438948 following 0.347799 hormone replacement therapy 0.348511	late effects 0.94258 treatment 0.571093 blood vessel 0.385075 primary cancer 0.359907 signs 0.42599 related health problems 0.511763 procedures 0.374731 National Cancer Institute 0.350345 spinal cord 0.453656 disease 0.351393 breast cancer risk 0.350432 breast cancer 0.372761 brain tumor 0.349819 thyroid late effects 0.395111 brain 0.380353 doctor 0.354325 radiation treatment 0.379126 radiation 0.476283 acute lymphoblastic leukemia 0.349699 health habits 0.363956 neuroendocrine late effects 0.359016 high blood pressure 0.347712 nonmelanoma skin cancer 0.356812 lung late effects 0.390136	CLICK HERE
1649	National Cancer Institute	Html	en	Aromatherapy and Essential Oils (PDQ®)–Patient Version	Expert-reviewed information summary about the use of aromatherapy and essential oils to improve the quality of life of cancer patients.	PDQ Aromatherapy 0.51751 cancer treatment 0.518478 modern aromatherapy 0.502296 certain essential oils 0.545828 aromatherapy training 0.496531 PDQ cancer information 0.582174 Cancer Complementary 0.49782 hormone -like effects 0.496783 clinical trials 0.646919 cancer information summary 0.54045 aromatherapy massage 0.496545 alternative cancer therapies 0.488792 clinical trial 0.515897 CAM cancer research 0.479249 patients 0.520207 cancer patients 0.499565 Aromatherapy products 0.529674 bergamot essential oil 0.494855 literature discuss aromatherapy 0.518185 NCI PDQ cancer 0.50787 cancer information database 0.486869 aromatherapy 0.710126 international aromatherapy programs 0.515466 Therapies Editorial Board 0.490712	essential oils 0.964677 cancer information 0.591001 treatment 0.540034 Complementary Therapies Editorial 0.514222 Drug Administration 0.547203 Cancer Information Specialist 0.481775 Aromatherapy research 0.515581 tree essential oils 0.64448 Cancer Information Service 0.537651 tree essential oil 0.496279 Antibacterial essential oils 0.531896 National Cancer Institute 0.639762 alternative medicine 0.561892 standard aromatherapy certification 0.518782 term aromatherapy 0.502247 orange essential oil 0.494346 aromatherapy courses 0.496618 tea tree 0.549957 cancer clinical trials 0.48888 alternative therapies 0.505894 ginger essential oil 0.493305 cancer information summaries 0.487611 cancer 0.667969 Holistic Aromatherapy 0.506338	CLICK HERE
1661	National Cancer Institute	Html	en	Antineoplastons (PDQ®)–Health Professional Version	Expert-reviewed information summary about antineoplastons as a treatment for people with cancer.	various tumor suppressor 0.673325 high-risk pediatric patients 0.613742 cell lines 0.732784 antineoplaston A10. 0.614589 steady state concentration 0.632482 mean steady state 0.62987 stable disease 0.629423 tumor suppressor genes 0.670419 antineoplaston a10 0.785651 multiple brain metastases 0.666381 clinical trials 0.642258 cancer cell line 0.621623 cancer information summary 0.628466 highest tumor response 0.628298 patients 0.960903 cancer patients 0.782838 average dose 0.662612 human colon cancer 0.66679 tumor progression 0.629611 colon cancer cells 0.664834 antineoplaston treatment 0.679278 complete tumor response 0.726436 metastatic brain tumor 0.711993 study 0.663173 neutrophil apoptosis 0.623745	Human/Clinical Studies section 0.637915 neoplastic cell lines 0.689948 human blood 0.654645 cancer cells 0.75191 animal tumor systems 0.612469 National Cancer Institute 0.656232 tumor growth 0.643714 breast cancer patients 0.772855 partial tumor response 0.663127 AS2-1 0.676129 antineoplaston therapy 0.747438 white blood cell 0.631532 antineoplaston A. 0.675544 abnormal cells 0.630356 human tumor tissue. 0.623365 human urine 0.617971 antineoplastons 0.86378 experimental cancer therapy 0.633011 chronic lymphocytic leukemia 0.610232 tumor response 0.767878 objective tumor response 0.612044 naturally occurring biochemical 0.637098 antineoplastons A10 0.665762 cancer 0.805413	CLICK HERE
2015	National Cancer Institute	Html	es	Prevención del cáncer de pulmón (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	cigarrillo encendido 0.533546 voluntarios sanos 0.521783 secciones llamadas lóbulos 0.564444 factor protector 0.54356 rayos x 0.525531 rayos gamma 0.526755 altas cantidades 0.523911 vías respiratorias 0.534485 suplementos vitamina 0.527073 membrana delgada llamada 0.563077 National Cancer Institute 0.526876 Más personas 0.538369 Instituto Nacional 0.548081	antecedentes familiares 0.770813 siguientes factores 0.598507 Physician Data Query 0.601335 gas radón 0.544843 prevención revisa 0.523285 PDQ Prevención 0.542908 siguientes sustancias 0.533013 Menor exposición 0.544963 órganos respiratorios 0.535883 principal causa 0.53309 factores protectores 0.947087 siguientes sumarios 0.567797 suplementos alimenticios 0.525893	CLICK HERE
2037	National Cancer Institute	Html	es	Prevención del cáncer de piel (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad.	skin cancer 0.991265 cutaneous melanoma 0.469757 Lippincott Williams 0.41932 skin cancer prevention 0.612003 prevent skin 0.440602 protectores solares 0.469609 Williams GM 0.418343 queratosis solares 0.585992 Sin embargo 0.685934 protector solar 0.843096 American Cancer Society 0.553421 Prev Med 0.458565 cancer prevention study 0.448174 case-control study 0.424296 Study Group 0.427125 DeVita VT Jr 0.43478 risk factors 0.435855 with nonmelanoma skin 0.42056 isotretinoin-basal cell carcinomas 0.418488 randomized trial 0.462527 exposición solar 0.710997 Natl Cancer Inst 0.487884 8th ed 0.41947 protección solar 0.624745 melanoma risk factors 0.418328	pruebas insuficientes 0.419855 Nambour Skin Cancer 0.466485 cell carcinomas 0.512878 Halliday GM 0.422507 Arch Dermatol 0.425176 Wilson LD 0.417928 Cancer Facts 0.43005 Aasi SZ 0.421096 nevos melanocíticos benignos 0.418665 protector solar ayuda 0.422241 controlled trial 0.45893 protector solar versus 0.425736 Epidemiol Biomarkers Prev 0.463973 exposición solar aguda 0.467654 Cancer Prevention Trial 0.454925 Thomas VD 0.418204 Reduce Actinic Cancer 0.419285 radiación uv 0.425436 randomized controlled trial 0.440826 radiación solar 0.432514 crema base 0.420169 nonmelanoma skin cancer 0.715174 radiación ultravioleta 0.572893 Cancer Study Group 0.420229	CLICK HERE
2079	National Cancer Institute	Html	es	BRCA1 y BRCA2: Riesgo de cáncer y pruebas genéticas	Hoja informativa acerca de los genes BRCA1 y BRCA2, de qué hacer si una persona tiene resultados positivos para una de estas alteraciones, y de las consecuencias de las pruebas genéticas.	with inherited mutations 0.40971 Fanconi anemia 0.442696 general padecerán cáncer 0.476912 Lubinski J 0.414965 Cancer Statistics Review 0.41308 brca1 or brca2 0.539593 largo plazo 0.414755 American Cancer Society 0.413258 posibles perjuicios 0.41059 Biallelic mutations 0.410182 National Comprehensive Cancer 0.413868 Breast Cancer Research 0.418728 with brca1 or 0.423664 Múltiples cánceres 0.410805 mutaciones específicas dañinas 0.471623 brca2 mutations 0.589927 among male brca1 0.421616 or genetic predisposition 0.416124 BRCA2 padecerán 0.44228 gen palb2 0.413362 BRCA1 mutation carriers 0.444383 Estados Unidos 0.427518 padecerán cáncer 0.566332 mutaciones dañinas 0.851633 PubMed Abstract 0.989166	mutation carriers identified 0.410419 seno masculino 0.429589 Clinical Oncology 0.441136 BRCA2 carriers 0.419799 risks among brca1 0.420776 BRCA2 mutation carriers 0.508942 BRCA2 mutations detected 0.422577 contralateral breast 0.413156 National Cancer Institute 0.442375 Cancer Research 0.430441 Breast Cancer Prevention 0.417323 antecedentes familiares 0.783866 or brca2 mutations 0.503006 mutation carriers with 0.423928 breast cancer 0.531052 clinical breast examination 0.410267 mujeres padecerán 0.409393 mujeres portadoras 0.421608 gen brca1 0.536899 asesoría genética 0.435987 cancer risk 0.445775 New England Journal 0.415366 bilateral profiláctica 0.437879 BRCA2 mutations account 0.4223	CLICK HERE
16716	National Cancer Institute	Html	en	NCI Cancer Moonshot℠ Public Access and Data Sharing Policy	NCI has established a data sharing policy that supports open, public access to all research and data for projects funded as part of the Cancer Moonshot. Find details on the policy.	Underlying Primary Data 0.835591 National Cancer Advisory 0.204571 Creative Commons 0.266314 Cancer Moonshotâ„  0.229846 Moonshot Research Project 0.326921 public domain tool 0.238273 extramural Cancer Moonshot 0.217832 Cancer Moonshot beginning 0.210573 cancer research 0.226051 Data Sharing Repositories 0.219342 underlying data 0.223365 NIH Sharing Policies 0.206938 Genomic Data Sharing 0.238331 Moonshot Research Projects 0.712789 Cancer Moonshotâ„  Research 0.221203 NIH Data Sharing 0.283755 National Cancer Institute 0.205263 Cancer Moonshot Projects 0.211704 public access 0.827988	Blue Ribbon Panel 0.23172 Cancer Moonshot Research 0.963477 independent data access 0.222133 data sharing policies 0.240205 Public Access Policy. 0.214656 nih public access 0.329101 Genomic Data Commons 0.208284 Enhanced Data Sharing 0.250631 Public Access Policy 0.237717 NCI-Supported Cancer Moonshot 0.379658 appropriate Public Access 0.254192 cancer research projects 0.217712 NCI researchers 0.205129 NCI intramural Cancer 0.231006 Data Sharing Policy 0.330676 Rule.7 Underlying Primary 0.217644 Data Sharing Plan 0.965755 intramural Cancer Moonshot 0.258314 Cancer Moonshot Public 0.244424	CLICK HERE
16848	National Cancer Institute	Html	en	Treatment and Therapy	Nanotechnology offers the means to target therapies directly and selectively to cancerous cells and neoplasms. With these tools, clinicians can safely and effectively deliver chemotherapy, radiotherapy, and the next generation of immuno- and gene therapies to the tumor. Futhermore, surgical resection of tumors can be guided and enhanced by way of nanotechnology tools. Find out how nanotechnology will offer the next generation of our therapeutic arsenal to the patient.	cancer treatment 0.854097 tumor type 0.82492 tumor tissues 0.889211 Cancer therapies 0.820703 large surface area 0.827043 nanoparticles 0.943843 superficial tumor 0.871555 nanotechnology cancer therapy 0.925806 multiple myeloma patients 0.821624 RNA-based genetic therapeutics 0.82576 cancer therapeutics 0.879587 vivo RNA nanoparticle 0.839578 nucleic acids 0.851966 electromagnetic radiation modalities 0.829021 cancer immunotherapy deepens 0.869884 artificial antigen 0.824529 Host Cell Response 0.906892 radiation therapy 0.999924 Standalone nanoparticle vaccines 0.835115 multiple dendritic cell 0.822099 conventional radiation therapy 0.856977 tumor vasculature permeability 0.888964 Cancer Nanotechnology Excellence 0.870289 tumor mass 0.82439	photodynamic therapy 0.836532 Cancer Nanotechnology awardees 0.958295 cancer cells 0.999243 external radiation sources 0.839028 small molecule compounds 0.820814 Cancer Therapy Center 0.956254 form Cherenkov radiation 0.829553 tumor accumulation 0.82268 atomic number nanoparticles 0.859022 Biology Cancer Center 0.860679 current radiotherapy dosage 0.82716 delivery 0.878526 combination drug delivery 0.856304 current treatment modalities 0.839227 superficial tumor sites 0.867918 innovative nanoparticle packages 0.854373 Gene silencing therapeutics 0.826818 tissue tumor targets 0.869042 electromagnetic radiation 0.829381 nanomaterial-based delivery platforms 0.862296 external electromagnetic radiation 0.823812 tumor 0.913691 tumor microenvironment 0.865684 deep tissue tumors 0.824773	CLICK HERE
17234	National Cancer Institute	Html	en	Adding Immune-based Treatments to Standard Glioblastoma Therapy	This clinical trial is testing standard therapy (surgery, radiation and temozolomide) plus immunotherapy with pembrolizumab with or without a cancer treatment vaccine for patients with newly diagnosed glioblastoma, a common and deadly type of brain tumor.	immune checkpoint inhibitor 0.991382 Dr. Gilbert 0.728039 tumor tissue 0.405841 trial contact information 0.29929 experimental vaccine 0.247456 1-year overall survival 0.300393 NCI’s Cancer 0.233291 Treating Patients 0.208707 little tumor tissue 0.376059 standard therapy plus 0.329661 immune response 0.550076 NCI Clinical Trials 0.330246 chemotherapy drug temozolomide 0.399109 cancer treatment vaccine 0.66133 primary brain tumor 0.428278 Cancer Research 0.215559 clinical trials 0.480839	slow tumor growth 0.416918 partially randomized phase 0.30891 patients 0.251176 Mark R. Gilbert 0.399405 tumor-specific vaccine 0.249165 experimental cancer treatment 0.582716 immune checkpoint inhibitors 0.542772 microscopic tumor 0.266367 newly diagnosed glioblastoma 0.842005 Current standard therapy 0.36143 placebo vaccine 0.253985 immunotherapy drug pembrolizumab 0.351275 median survival time 0.347591 protocol summary 0.359999 radiation therapy 0.342013 standard therapy 0.747186	CLICK HERE